Who are Nivolumab + Relatlimab's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): TAR-210, BAT2206, AK112, Gemcitabine, Cisplatin, AK112, Carboplatin, Paxlitaxel, Nivolumab-relatlimab FDC.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/nivolumab-relatlimab.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Nivolumab + Relatlimab — Competitive Intelligence Brief

Nivolumab + Relatlimab (Nivolumab + Relatlimab) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Dual checkpoint inhibitor (PD-1 and LAG-3 inhibitor combination). Area: Oncology.

marketed Dual checkpoint inhibitor (PD-1 and LAG-3 inhibitor combination) PD-1 and LAG-3 Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Nivolumab + Relatlimab (Nivolumab + Relatlimab) — H. Lee Moffitt Cancer Center and Research Institute. Nivolumab and relatlimab together block two immune checkpoints (PD-1 and LAG-3) to enhance T-cell activation and anti-tumor immunity.

Comparator set (5 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Nivolumab + Relatlimab TARGET	Nivolumab + Relatlimab	H. Lee Moffitt Cancer Center and Research Institute	marketed	Dual checkpoint inhibitor (PD-1 and LAG-3 inhibitor combination)	PD-1 and LAG-3
TAR-210	TAR-210	Janssen Research & Development, LLC	phase 3	Bispecific antibody	PD-1 and LAG-3
BAT2206	BAT2206	Bio-Thera Solutions	phase 3	Bispecific antibody; dual checkpoint inhibitor	Likely PD-1 and LAG-3 (or similar dual checkpoint targets)
AK112, Gemcitabine, Cisplatin	AK112, Gemcitabine, Cisplatin	Akeso	phase 3	Bispecific antibody (PD-1/LAG-3 inhibitor) combined with chemotherapy	PD-1 and LAG-3
AK112, Carboplatin, Paxlitaxel	AK112, Carboplatin, Paxlitaxel	Akeso	phase 3	Bispecific antibody (PD-1/LAG-3 inhibitor) + chemotherapy combination	PD-1 and LAG-3
Nivolumab-relatlimab FDC	Nivolumab-relatlimab FDC	Bristol-Myers Squibb	phase 3	Dual checkpoint inhibitor (PD-1/LAG-3)	PD-1 and LAG-3

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Dual checkpoint inhibitor (PD-1 and LAG-3 inhibitor combination) class)

H. Lee Moffitt Cancer Center and Research Institute · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Nivolumab + Relatlimab — Competitive Intelligence Brief. https://druglandscape.com/ci/nivolumab-relatlimab. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab